. Author manuscript; available in PMC: 2010 May 1.

Published in final edited form as: J Immunol. 2009 May 1;182(9):5547–5559. doi: 10.4049/jimmunol.0802077

Table IV.

Effects of LPS on the establishment of hematopoietic chimerism are dependent on the time of administration^a

Group	TLR Agonist	Chimerism Frequency (%)	Donor Origin PBMCs at 8 wk (%)
1	None	6/7 (85.7%)	3.20 ± 1.84
2	LPS (given on day −8)	6/7 (85.7%)	4.93 ± 2.04
3	LPS (given on day −7)	0/7 (0)^b	<0.10
4	LPS (given on day +1)	0/7 (0%)^b	<0.10

C57BL/6 mice were treated with BALB/c DST, anti-CD154 mAb, and transplanted with BALB/c bone marrow according to our standard protocol without (group 1) or with an i.p. injection of 100 µg of LPS 24 h before DST and anti-CD154 mAb (group 2), on the day of DST and anti-CD154mAb (group 3) or 24 h after bone marrow transplantation (group 4). Hematopoietic chimerism was defined as >0.10% donor origin PBMCs 8 wk after bone marrow injection. Percent donor origin bone marrow cells is the mean ± SD chimerism levels in chimeric mice. For groups with no chimeric mice, we used the limit of detection (<0.10) to indicate a lack of chimerism. Data are pooled from two independent experiments.

p = 0.0012 vs groups 1 and 2.